Drug Database
HY

hyaluronic acid (BioHy / Euflexxa / BioLon)

✓ Approved

Johnson & Johnson Services, Inc. · therapeutic agent

What is hyaluronic acid?

hyaluronic acid is a therapeutic agent developed by Johnson & Johnson Services, Inc.. It is approved for therapeutic indications via injectable (others) or intraarticular injection.

Drug Profile

Brand NamesBioHy, Euflexxa, BioLon
CompanyJohnson & Johnson Services, Inc.
RouteInjectable (Others), Intraarticular Injection
StatusApproved
Sources: ClinicalTrials.gov, Johnson & Johnson Services, Inc.

Therapeutic Indications

hyaluronic acid is developed for 4 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Eye disordersGlaucoma✓ Approved
Musculoskeletal and connective tissue disordersOsteoarthritis✓ Approved
Surgical and medical proceduresAdjuvant therapy✓ Approved
Eye disordersDry eyePhase II

Related Research Articles

PubMedAmerican journal of ophthalmology2026-08-30

Biomaterials in Retinal Surgery: Engineering the Future.

Dindar Ismail Ahmed IA, Shoichet Molly S MS, Labriola Jonathan J, Forman Adam A et al.

To review current and emerging biomaterials in retinal surgery - vitreous tamponade agents, retinal prostheses, retinal pigment epithelium (RPE) transplant scaffolds, intraocular drug delivery platforms, and gene therapy vectors - with emphasis on the authors' oxime-crosslinked hyaluronic acid vitreous substitute. Narrative expert review. Systematic review methodology was not used; no protocol registration, pre-specified eligibility criteria, dual independent screening, or PRISMA flow diagram was undertaken. Published preclinical animal studies, Phase I-III clinical trials, US Food and Drug Administration approvals, and real-world evidence on biomaterials in posterior segment surgery. No individual patient data were accessed. A structured literature search of PubMed/MEDLINE, supplemented by Google Scholar, was performed from January 2018 to March 2026 across five domains: vitreous tamponade agents; retinal prostheses; scaffold-based RPE transplantation; nanoparticle and sustained-release drug delivery; and gene therapy vectors. Peer-reviewed investigations, trial reports, and regulatory data were prioritized. The authors' preclinical hydrogel data are presented as original data within a review context. Best-corrected visual acuity, intraocular pressure, electroretinography, retinal microstructure on optical coherence tomography, prosthetic visual acuity, ellipsoid zone area loss, injection frequency, and in vivo biocompatibility. The PRIMA photovoltaic subretinal implant produced a clinically meaningful improvement in visual acuity in 26 of 32 patients (81%) with geographic atrophy at 12 months. A 44-channel suprachoroidal prosthesis showed no device-related serious adverse events at 2.7 years. The authors' oxime-crosslinked hyaluronic acid hydrogel demonstrated density 1.01 g/mL and refractive index 1.356, with preserved electroretinography and intraocular pressure of 13.5-25.9 mmHg in rabbits. Scaffold-based RPE transplantation has entered Phase I/IIa trials. 2025 approvals included a refillable ranibizumab port delivery system for diabetic retinopathy and the first encapsulated cell therapy implant for macular telangiectasia type 2. Three Phase 3 anti-VEGF gene therapy trials are ongoing. Biomaterial engineering is transforming retinal disease management from stabilization toward tissue replacement and vision restoration. Principal limitations are the preclinical status of the hydrogel data and early-phase status of RPE scaffold trials. Outstanding challenges include long-term in vivo stability, immunological management of allogeneic constructs, scalable manufacturing, and definitive efficacy trials.

PMID 42669344
Read full article →
PubMedMaterials today. Bio2026-08-30

Porphyrin-copper (II) covalent organic framework nanoplatform with intrinsic bifunctional photodynamic and chemodynamic activities for synergistic multimodal cancer therapy.

Mo Yongjie Y, Hou Jie J, Li Hongli H, Wang Lijuan L et al.

Photodynamic therapy (PDT) efficacy is severely compromised by tumor hypoxia and the scarcity of efficient type-I photosensitizers, necessitating multimodal therapeutic strategies. Herein, we report a porphyrin-Cu (II) covalent organic framework (TBCOF) with intrinsic bifunctional photodynamic and chemodynamic activities. Sequential DOX encapsulation and hyaluronic acid (HA) surface functionalization afford HA-TBCOF@DOX, a tumor-targeted nanoplatform integrating four synergistic therapeutic modalities. Under 660 nm laser irradiation, the nanoplatform generates ROS signatures consistent with both type-I and type-II pathways for PDT, while the intrinsic Cu2+ centers are proposed to catalyze a Fenton-like reaction consistent with •OH generation for CDT. Concurrently, observations of O2 evolution suggest catalase-like activity that may decompose endogenous H2O2 into O2, alleviating hypoxia and potentiating oxygen-dependent PDT. Efficient photothermal conversion and pH-triggered DOX release contribute to photothermal and chemotherapeutic effects, respectively, while HA-mediated CD44 targeting enhances cellular uptake and therapeutic specificity. In vitro and in vivo studies demonstrate that laser-activated HA-TBCOF@DOX effectively suppresses tumor growth, induces apoptosis, and exhibits no apparent systemic toxicity under the tested experimental conditions. This work establishes a multifunctional COF-based nanoplatform that addresses PDT limitations observed in this study by integrating intrinsic PDT and CDT, providing a robust strategy for synergistic multimodal cancer therapy.

PMID 42668618
Read full article →
PubMedThe journal of allergy and clinical immunology. Global2026-08-30

ALOX15-driven ω-6 fatty acid metabolism promotes type 2 inflammation in eosinophilic chronic rhinosinusitis with nasal polyps.

Sakashita Masafumi M, Kidoguchi Masanori M, Imoto Yoshimasa Y, Sato Yohei Y et al.

Local lipid metabolism contributes to immune homeostasis in the nasal mucosa and the pathogenesis of chronic rhinosinusitis. However, lipid mediator networks underlying eosinophilic chronic rhinosinusitis (ECRS) remain poorly defined. To characterize fatty acid-derived lipid mediator profiles in nasal polyps (NPs) from patients with and without ECRS and identify pathways associated with eosinophilic inflammation. Lipidomic profiling was performed using LC-MS/MS on NP tissues from patients with ECRS (n = 4) and without ECRS (n = 4). A total of 158 ω-6 and ω-3 fatty acid-derived lipid mediators were quantified. Arachidonate 15-lipoxygenase (ALOX15) pathway activity was evaluated by quantitative PCR and ELISA. ECRS NPs displayed a distinct lipidomic signature compared with non-ECRS NPs. ECRS NPs exhibited increased levels of proinflammatory ω-6 fatty acid metabolites, including 15-hydroxyeicosatetraenoic acid (15-HETE) and 13-hydroxyoctadecadienoic acid, along with elevated ALOX15 pathway products and higher ALOX15 mRNA expression. Anti-inflammatory specialized proresolving mediators, such as lipoxin A4, were also elevated within the ω-6 pathway, and lipoxin A4 levels correlated with 15-HETE levels. These patterns indicate the concurrent activation of pro- and anti-inflammatory pathways, with a predominance of ALOX15-driven ω-6 metabolites in ECRS. In contrast, the ω-3 fatty acid pathway showed only modest increases in 14,15-DiHETE and resolvin D2, suggesting a limited compensatory resolution response compared with the robust ALOX15-dependent ω-6 activity. ECRS NPs exhibit a skewed lipid mediator profile characterized by enhanced ALOX15-dependent ω-6 metabolism and insufficient resolution activity. This imbalance may underlie persistent type 2 inflammation in ECRS and suggests that targeting the 15-lipoxygenase pathway may offer therapeutic benefits.

PMID 42668469
Read full article →
PubMedFood chemistry: X2026-08-30

Effect of solid-state fermentation on the release and antioxidant activity of soluble polyphenols from wheat bran.

Tian Xiaomin X, Guo Yuqiu Y, Sun Linlin L, Chen Lirong L et al.

Using wheat bran as substrate, four solid-state fermentation methods were compared for soluble polyphenol release. The effect of Bio-enzymatic synergy (BES) is the most significant, producing 4.85 mg GAE/g of total phenolic substances, which is 45.77% higher than the control group (CK). LC-MS analysis revealed that ferulamide and 2,4,6-trihydroxybenzoic acid predominated in positive ion mode, while salicylic acid dominated in negative mode. Notably, salicylic acid was found almost exclusively in ester-bound and glycoside-bound fractions (>88%), indicating its release requires cleavage of covalent linkages to cell wall components. The release of salicylic acid results from the synergistic action of Bio-enzymatic synergy and alkaline hydrolysis. Both in vitro and in vivo assays confirmed that BES-released polyphenols enhanced antioxidant activity, reducing ROS and MDA levels while increasing GSH-Px activity and extending C. elegans lifespan. These findings provide a mechanistic basis for developing targeted fermentation-enzymatic processes to produce functional wheat bran extracts.

PMID 42668496
Read full article →
PubMedFood chemistry: X2026-08-30

Comprehensive analysis of the effects of foliar application of the synthetic strigolactone analog GR24 during the growth period on postharvest quality and metabolic indicators of pak choi.

Ma Yufeng Y, Cai Qitong Q, Wang Cheng C, Liu Yang Y et al.

Strigolactones (SLs) regulate plant growth and metabolism, but their concentration-dependent effects on leafy vegetable quality remain unclear. We investigated how the synthetic SL analog GR24 affects physiological and metabolic processes in pak choi (Brassica rapa subsp. chinensis). Mantel correlation analysis and partial least squares structural equation modeling (PLS-SEM) revealed distinct response patterns. The 1 μmol·L-1 treatment (T2) enhanced photosynthesis, carbon‑nitrogen assimilation, mineral accumulation, and GA3, ZT, ABA, and JA levels, whereas the 10 μmol·L-1 treatment (T3) promoted carotenoid and phenolic accumulation, including rutin, ferulic acid, and caffeic acid. Multivariate analysis linked phenolic acid accumulation mainly to nitrogen and amino acid metabolism, with additional associations with P status. Overall, T2 broadly enhanced primary metabolism and nutrition, whereas T3 favored secondary and antioxidant-related metabolism, providing a framework for optimizing GR24 application in high-quality leafy vegetable production.

PMID 42668560
Read full article →
PubMedInternational journal of pharmaceutics: X2026-08-30

Optimizing nucleic acid delivery using PF14 peptide and lipid nanoparticle systems.

Daniele Delia D, Hein Zaw Myo ZM, Saher Osama O, El-Serafi Ibrahim I

Nucleic acid-based therapeutics are a rapidly expanding class of precision medicines capable of directly modulating gene expression. However, their clinical application is limited by challenges in cellular delivery, including large molecular size, hydrophilicity, and susceptibility to enzymatic degradation. To address these barriers, advanced delivery platforms such as cell-penetrating peptides and lipid nanoparticles (LNPs) have been developed. This study evaluates two delivery systems: the cell-penetrating peptide PepFect-14 (PF14) and LNP formulations, for enhancing nucleic acid delivery and cellular uptake. PF14 facilitates intracellular transport through peptide-nucleic acid complex formation, while LNPs protect cargo from degradation and can promote endosomal escape. Their performance was assessed under different conditions using luciferase-based reporter systems in HeLa cells. PF14-mediated delivery of the splice-switching oligonucleotide ON-705 in HeLa 705 cells showed efficient splice correction, with activity increasing in a dose- and molar ratio- dependent manner, reaching a plateau at a 1:10 ratio. Delivery efficiency was significantly influenced by formulation conditions, with Opti-MEM outperforming standard media and sugar-based buffers. Polymer excipients also affected activity as PVA18, PVA40, and PVP40 enhanced performance, while low molecular weight PVP reduced efficacy. In parallel, LNP-mediated delivery of luciferase mRNA in wild-type HeLa cells demonstrated robust, dose-dependent protein expression. Both systems maintained high cell viability (80-100%). Overall, these findings highlight the importance of formulation optimization in improving nucleic acid delivery and provide practical insights for enhancing peptide- and lipid-based therapeutic platforms.

PMID 42668503
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about hyaluronic acid